Sun Piaoyang built his pharmaceutical fortune by taking charge of a small state-led drugmaker, transforming it into Hengrui Pharma and later becoming the controlling shareholder of the listed company. [1][2]
He entered Hengrui as a manager, not an heir
Forbes says Sun Piaoyang became head of the state-led pharmaceutical company that became Hengrui in 1990 at age 32, rather than inheriting a family-owned drug business. [1]
The same profile credits Sun with turning the former state-led business into one of China's largest producers of anti-infection and cancer medicines before taking it public in Shanghai in 2000. [1]
Hengrui's Hong Kong prospectus records that Sun later became the largest shareholder of Hengrui Group in 2006, after earlier state-owned shares had been transferred into the group structure. [2]
Operating growth and ownership created the fortune
Hengrui now describes itself as a global innovation-driven pharmaceutical company with a large drug pipeline and dual listings in Shanghai and Hong Kong, reflecting the scale reached under Sun's long leadership. [3]
Sun's wealth therefore came from decades of operating transformation and ownership accumulated in the company he led, not from an inherited pharmaceutical fortune or family-controlled predecessor. [1][2]
Sources for background
Sources reviewed Sep 23, 2026.
- Sun Piaoyang · Forbes · Mar 10, 2026
- HISTORY AND CORPORATE STRUCTURE · Hengrui Pharma
- About Hengrui Pharma · Hengrui Pharma
Comparable Healthcare billionaires
Similar Healthcare billionaires by estimated net worth.
